Q1 FY27 results approved; PAT up, standalone revenue down sharply

Revenue declinedProfit growth above 25%Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹1.60

prior close

₹1.60

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-0.1% vs market

Civil Construction peers, median of 98sector-0.8%+0.2% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.2 pts more than its Civil Construction peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6-0.6-0.1-0.8+0.2

Next day

+0.0+0.5-0.5-0.6+0.6

+3.1+1.9+1.3+0.4+2.7

+3.8+2.3+1.5-0.2+4.0

+5.0+3.6+1.4+0.2+4.8

+3.8+4.0-0.2+0.0+3.8

+10.6+4.0+6.7+0.2+10.4

15d

+11.9+4.9+7.0-2.6+14.5

+13.1+5.9+7.2-3.3+16.4

+8.8+4.8+4.0-7.0+15.8

+6.9pendingpending-15.4+22.3

UpDownMarket · Nifty Microcap 250Sector · Civil Construction peers, median of 98Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q1 FY27 (June 2026) unaudited results. Standalone revenue fell 68% YoY to Rs 336.49 lakhs but PAT jumped to Rs 76.80 lakhs from Rs 32.89 lakhs. Consolidated revenue grew 5.7% to Rs 8022.22 lakhs with PAT up 81% to Rs 97.82 lakhs. Board also noted a business collaboration with Qness Pharmaceuticals. Auditor issued a clean limited review.

Likely market impact

Mixed picture. Weak standalone sales but strong profit growth on a low base. Subsidiary and JV lift consolidated numbers.